IMPPORT Trial (IMAGE)
Caption
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging.
Credit
Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
Usage Restrictions
Please give appropriate credit.
License
Original content